Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SUMIT MADAN

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1972766756
CMS profile
1103038
Location
GILBERT, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$200,018.18

200 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Celgene Corporation $53,634.68 51
Janssen Biotech, Inc. $51,915.13 50
Takeda Pharmaceuticals U.S.A., Inc. $48,152.52 36
Amgen Inc. $35,476.36 42
GENZYME CORPORATION $7,203.42 10
Janssen Scientific Affairs, LLC $3,320.00 2
Seattle Genetics, Inc. $121.57 1
SANOFI-AVENTIS U.S. LLC $63.09 2
TESARO, Inc. $59.01 1
Daiichi Sankyo Inc. $28.32 2
Astellas Pharma US Inc $25.31 2
Puma Biotechnology, Inc. $18.77 1

Page 3 of 4; records 101–150 of 200 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SUMIT MADAN

NPI 1972766756 · CMS profile ID 1103038

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

GILBERT, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 4; records 101–150 of 200 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1972766756?year=2019&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SUMIT MADAN, NPI 1972766756, CMS profile ID 1103038. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 200 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1972766756?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). SUMIT MADAN, NPI 1972766756, CMS profile ID 1103038. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 200 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1972766756?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
SUMIT MADAN, NPI 1972766756, CMS profile ID 1103038, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 200 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1972766756?year=2019&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

200 matching records · $200,018.18 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 200 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 200.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Amgen Inc. $29.0006/21/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 663089251 CMS
Amgen Inc. $27.0006/21/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 663089253 CMS
Amgen Inc. $67.7706/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 663089263 CMS
Amgen Inc. $20.0006/21/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 663089265 CMS
Celgene Corporation $94.6706/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672962895 CMS
Amgen Inc. $3,300.0006/18/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 663089257 CMS
Amgen Inc. $1,100.0006/18/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 663089259 CMS
Amgen Inc. $108.7406/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 663089247 CMS
Celgene Corporation $148.9205/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672837505 CMS
Celgene Corporation $188.0705/30/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672842148 CMS
Celgene Corporation $188.0605/30/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672842295 CMS
Celgene Corporation $82.6505/30/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672850326 CMS
Celgene Corporation $3,850.0005/30/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672850330 CMS
Celgene Corporation $339.1405/30/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672852695 CMS
Celgene Corporation $557.0005/30/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672852951 CMS
Celgene Corporation $1,977.5005/30/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672857991 CMS
Celgene Corporation $124.9905/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672880080 CMS
Celgene Corporation $339.1405/30/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672885789 CMS
Celgene Corporation $557.0005/30/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672885917 CMS
Celgene Corporation $1,977.5005/30/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673015665 CMS
Takeda Pharmaceuticals U.S.A., Inc. $215.8105/30/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697377237 CMS
Amgen Inc. $251.9605/28/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 663089269 CMS
Takeda Pharmaceuticals U.S.A., Inc. $945.0005/24/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697371837 CMS
Celgene Corporation $1,977.5005/21/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672841347 CMS
Celgene Corporation $1,342.7605/21/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672853596 CMS
Celgene Corporation $2,695.0005/21/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672869653 CMS
Celgene Corporation $124.9905/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673014770 CMS
Janssen Biotech, Inc. $500.0005/14/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658569617 CMS
Janssen Biotech, Inc. $3,800.0005/08/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658569613 CMS
Takeda Pharmaceuticals U.S.A., Inc. $203.8405/02/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697371835 CMS
Takeda Pharmaceuticals U.S.A., Inc. $52.5205/02/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697371841 CMS
Takeda Pharmaceuticals U.S.A., Inc. $28.4605/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697371845 CMS
Takeda Pharmaceuticals U.S.A., Inc. $6,600.0005/02/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697406773 CMS
Janssen Biotech, Inc. $644.7405/01/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658569605 CMS
Janssen Biotech, Inc. $35.6705/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658569609 CMS
Janssen Biotech, Inc. $30.0004/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658569601 CMS
Takeda Pharmaceuticals U.S.A., Inc. $458.0004/30/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697377233 CMS
Takeda Pharmaceuticals U.S.A., Inc. $6,600.0004/27/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697376873 CMS
Takeda Pharmaceuticals U.S.A., Inc. $154.8104/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697379263 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2,310.0004/26/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697374587 CMS
Takeda Pharmaceuticals U.S.A., Inc. $84.2504/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697379927 CMS
Astellas Pharma US Inc $11.9004/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 655670993 CMS
Celgene Corporation $1,456.2604/16/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672838363 CMS
Celgene Corporation $68.6604/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672841877 CMS
Celgene Corporation $1,977.5004/16/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672850623 CMS
Celgene Corporation $58.3204/16/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672853229 CMS
Celgene Corporation $1,574.3304/16/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672853235 CMS
Celgene Corporation $358.7804/16/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672866668 CMS
Celgene Corporation $3,850.0004/16/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672866675 CMS
Takeda Pharmaceuticals U.S.A., Inc. $383.7404/12/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697371831 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $200,018.18 200
PY2020 $87,143.66 69
PY2021 $43,472.69 44
PY2022 $43,963.14 35
PY2023 $11,047.27 17
PY2024 $22,827.85 18
PY2025 $13,648.02 31

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $950.00 2
PY2025 Principal investigator $1,350,325.59 91
PY2024 Principal investigator $672,726.55 94
PY2023 Recipient $750.00 2
PY2023 Principal investigator $828,879.81 58
PY2022 Recipient $1,000.00 3
PY2022 Principal investigator $1,219,403.43 83
PY2021 Recipient $750.00 2
PY2021 Principal investigator $2,098,761.08 102
PY2020 Principal investigator $512,970.34 8

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

93 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $1,241.00 12/29/2025 Covered Recipient Teaching Hospital
Banner Casa Grande Medical Center
A Phase 1 Randomized, Open-Label Pharmacokinetic Comparability Study Comparing Pre- and Post-change Teclistamab in Participants with Relapsed/Refractory Multiple Myeloma No dispute reported 06/30/2026 1175368706
Principal investigator 1 Janssen Research & Development, LLC $10,324.00 12/26/2025 Covered Recipient Teaching Hospital
Banner Casa Grande Medical Center
A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants with Newly Diagnosed Multiple Myeloma Who are Either Ineligible or not Intended for Autologous Stem Cell Transplant as Initial Therapy. No dispute reported 06/30/2026 1175368749
Principal investigator 1 Janssen Research & Development, LLC $1,512.00 12/22/2025 Covered Recipient Teaching Hospital
Banner Casa Grande Medical Center
A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who have Received 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Monoclonal Antibody and Lenalidomide No dispute reported 06/30/2026 1175368571
Principal investigator 1 Janssen Research & Development, LLC $17,696.00 12/15/2025 Covered Recipient Teaching Hospital
Banner Casa Grande Medical Center
A Phase 1 Randomized, Open-Label Pharmacokinetic Comparability Study Comparing Pre- and Post-change Teclistamab in Participants with Relapsed/Refractory Multiple Myeloma No dispute reported 06/30/2026 1175368714
Principal investigator 1 Janssen Research & Development, LLC $280.00 12/04/2025 Covered Recipient Teaching Hospital
Banner Casa Grande Medical Center
A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who have Received 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Monoclonal Antibody and Lenalidomide No dispute reported 06/30/2026 1175368524
Principal investigator 1 Janssen Research & Development, LLC $2,241.00 12/01/2025 Covered Recipient Teaching Hospital
Banner Casa Grande Medical Center
A Phase 1 Randomized, Open-Label Pharmacokinetic Comparability Study Comparing Pre- and Post-change Teclistamab in Participants with Relapsed/Refractory Multiple Myeloma No dispute reported 06/30/2026 1175368741
Principal investigator 1 BeOne Medicines Ltd. $52,400.00 11/17/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190337165
Recipient PFIZER INC. $620.00 11/10/2025 Covered Recipient Physician ELRANATAMAB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228803202
Principal investigator 1 Janssen Research & Development, LLC $9,538.00 11/07/2025 Covered Recipient Teaching Hospital
Banner Casa Grande Medical Center
A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who have Received 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Monoclonal Antibody and Lenalidomide No dispute reported 06/30/2026 1175368634
Principal investigator 1 Janssen Research & Development, LLC $38,150.00 11/07/2025 Covered Recipient Teaching Hospital
Banner Casa Grande Medical Center
A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants with Newly Diagnosed Multiple Myeloma Who are Either Ineligible or not Intended for Autologous Stem Cell Transplant as Initial Therapy. No dispute reported 06/30/2026 1175368734
Principal investigator 1 BeOne Medicines Ltd. $161.00 10/27/2025 Covered Recipient Teaching Hospital
Banner Casa Grande Medical Center
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients with B-cell Malignancies No dispute reported 06/30/2026 1190334484
Principal investigator 1 Janssen Research & Development, LLC $650.00 10/27/2025 Covered Recipient Teaching Hospital
Banner Casa Grande Medical Center
A Phase 1 Randomized, Open-Label Pharmacokinetic Comparability Study Comparing Pre- and Post-change Teclistamab in Participants with Relapsed/Refractory Multiple Myeloma No dispute reported 06/30/2026 1175368684
Principal investigator 1 Janssen Research & Development, LLC $11,790.00 10/24/2025 Covered Recipient Teaching Hospital
Banner Casa Grande Medical Center
A Phase 1 Randomized, Open-Label Pharmacokinetic Comparability Study Comparing Pre- and Post-change Teclistamab in Participants with Relapsed/Refractory Multiple Myeloma No dispute reported 06/30/2026 1175368595
Principal investigator 1 Janssen Research & Development, LLC $6,199.00 10/17/2025 Covered Recipient Teaching Hospital
Banner Casa Grande Medical Center
A Phase 1 Randomized, Open-Label Pharmacokinetic Comparability Study Comparing Pre- and Post-change Teclistamab in Participants with Relapsed/Refractory Multiple Myeloma No dispute reported 06/30/2026 1175368640
Principal investigator 1 Janssen Research & Development, LLC $22,212.65 10/09/2025 Covered Recipient Teaching Hospital
Banner Casa Grande Medical Center
A Phase 1 Randomized, Open-Label Pharmacokinetic Comparability Study Comparing Pre- and Post-change Teclistamab in Participants with Relapsed/Refractory Multiple Myeloma No dispute reported 06/30/2026 1175368659
Principal investigator 1 BeOne Medicines Ltd. $1,304.80 10/08/2025 Covered Recipient Teaching Hospital
Banner Casa Grande Medical Center
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients with B-cell Malignancies No dispute reported 06/30/2026 1190334667
Principal investigator 1 Janssen Research & Development, LLC $8,948.00 09/22/2025 Covered Recipient Teaching Hospital
Banner Casa Grande Medical Center
A Phase 1 Randomized, Open-Label Pharmacokinetic Comparability Study Comparing Pre- and Post-change Teclistamab in Participants with Relapsed/Refractory Multiple Myeloma No dispute reported 06/30/2026 1175368827
Principal investigator 1 BeOne Medicines Ltd. $1,304.80 09/10/2025 Covered Recipient Teaching Hospital
Banner Casa Grande Medical Center
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190327403
Principal investigator 1 BeOne Medicines Ltd. $161.00 09/10/2025 Covered Recipient Teaching Hospital
Banner Casa Grande Medical Center
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190343285
Principal investigator 1 Janssen Research & Development, LLC $2,489.00 09/01/2025 Covered Recipient Teaching Hospital
Banner Casa Grande Medical Center
A Phase 1 Randomized, Open-Label Pharmacokinetic Comparability Study Comparing Pre- and Post-change Teclistamab in Participants with Relapsed/Refractory Multiple Myeloma No dispute reported 06/30/2026 1175368600
Principal investigator 1 Janssen Research & Development, LLC $29,800.00 09/01/2025 Covered Recipient Teaching Hospital
Banner Casa Grande Medical Center
A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who have Received 1 to 3 Prior Lines of Ther No dispute reported 06/30/2026 1175368666
Principal investigator 1 Janssen Research & Development, LLC $1,060.00 09/01/2025 Covered Recipient Teaching Hospital
Banner Casa Grande Medical Center
A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who have Received 1 to 3 Prior Lines of Ther No dispute reported 06/30/2026 1175368839
Principal investigator 1 BeOne Medicines Ltd. $52,400.00 08/25/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190344185
Principal investigator 1 Janssen Research & Development, LLC $14,552.00 08/25/2025 Covered Recipient Teaching Hospital
Banner Casa Grande Medical Center
A Phase 1 Randomized, Open-Label Pharmacokinetic Comparability Study Comparing Pre- and Post-change Teclistamab in Participants with Relapsed/Refractory Multiple Myeloma No dispute reported 06/30/2026 1175368834
Principal investigator 1 BeOne Medicines Ltd. $1,000.00 08/22/2025 Covered Recipient Teaching Hospital
Banner Casa Grande Medical Center
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190327361
Principal investigator 1 BeOne Medicines Ltd. $3,000.00 08/22/2025 Covered Recipient Teaching Hospital
Banner Casa Grande Medical Center
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190327363
Principal investigator 1 BeOne Medicines Ltd. $2,310.00 08/22/2025 Covered Recipient Teaching Hospital
Banner Casa Grande Medical Center
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190331815
Principal investigator 1 BeOne Medicines Ltd. $500.00 08/22/2025 Covered Recipient Teaching Hospital
Banner Casa Grande Medical Center
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190331845
Principal investigator 1 BeOne Medicines Ltd. $9.84 08/22/2025 Covered Recipient Teaching Hospital
Banner Casa Grande Medical Center
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190331853
Principal investigator 1 BeOne Medicines Ltd. $670.60 08/22/2025 Covered Recipient Teaching Hospital
Banner Casa Grande Medical Center
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190331865
Principal investigator 1 BeOne Medicines Ltd. $1,960.00 08/22/2025 Covered Recipient Teaching Hospital
Banner Casa Grande Medical Center
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190343163
Principal investigator 1 BeOne Medicines Ltd. $1,000.00 08/22/2025 Covered Recipient Teaching Hospital
Banner Casa Grande Medical Center
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190343187
Principal investigator 1 BeOne Medicines Ltd. $485.80 08/22/2025 Covered Recipient Teaching Hospital
Banner Casa Grande Medical Center
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190343263
Principal investigator 1 BeOne Medicines Ltd. $2,450.00 08/22/2025 Covered Recipient Teaching Hospital
Banner Casa Grande Medical Center
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190343277
Principal investigator 1 Janssen Research & Development, LLC $1,560.00 08/22/2025 Covered Recipient Teaching Hospital
Banner Casa Grande Medical Center
A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who have Received 1 to 3 Prior Lines of Ther No dispute reported 06/30/2026 1175368769
Principal investigator 1 Janssen Research & Development, LLC $41,835.00 08/21/2025 Covered Recipient Teaching Hospital
Banner Casa Grande Medical Center
A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who have Received 1 to 3 Prior Lines of Ther No dispute reported 06/30/2026 1175368787
Principal investigator 1 Janssen Research & Development, LLC $6,731.00 08/11/2025 Covered Recipient Teaching Hospital
Banner Casa Grande Medical Center
A Phase 1 Randomized, Open-Label Pharmacokinetic Comparability Study Comparing Pre- and Post-change Teclistamab in Participants with Relapsed/Refractory Multiple Myeloma No dispute reported 06/30/2026 1175368857
Principal investigator 1 Karyopharm Therapeutics Inc. $3,445.00 08/06/2025 Non-covered Recipient Entity
Banner MD Anderson Cancer Center
A Phase 1b/2 Study of Selinexor (KPT-330) in Combination with Backbone Treatments for Resistant/Refractory Multiple Myeloma No dispute reported 06/30/2026 1246662700
Principal investigator 1 Karyopharm Therapeutics Inc. $2,481.00 08/06/2025 Non-covered Recipient Entity
Banner MD Anderson Cancer Center
A Phase 1b/2 Study of Selinexor (KPT-330) in Combination with Backbone Treatments for Resistant/Refractory Multiple Myeloma No dispute reported 06/30/2026 1246662706
Principal investigator 1 Karyopharm Therapeutics Inc. $750.00 08/06/2025 Non-covered Recipient Entity
Banner MD Anderson Cancer Center
A Phase 1b/2 Study of Selinexor (KPT-330) in Combination with Backbone Treatments for Resistant/Refractory Multiple Myeloma No dispute reported 06/30/2026 1246662708
Principal investigator 1 Karyopharm Therapeutics Inc. $400.00 08/06/2025 Non-covered Recipient Entity
Banner MD Anderson Cancer Center
A Phase 1b/2 Study of Selinexor (KPT-330) in Combination with Backbone Treatments for Resistant/Refractory Multiple Myeloma No dispute reported 06/30/2026 1246662712
Principal investigator 1 Karyopharm Therapeutics Inc. $400.00 08/06/2025 Non-covered Recipient Entity
Banner MD Anderson Cancer Center
A Phase 1b/2 Study of Selinexor (KPT-330) in Combination with Backbone Treatments for Resistant/Refractory Multiple Myeloma No dispute reported 06/30/2026 1246662714
Principal investigator 1 Karyopharm Therapeutics Inc. $500.00 08/06/2025 Non-covered Recipient Entity
Banner MD Anderson Cancer Center
A Phase 1b/2 Study of Selinexor (KPT-330) in Combination with Backbone Treatments for Resistant/Refractory Multiple Myeloma No dispute reported 06/30/2026 1246662716
Principal investigator 1 Karyopharm Therapeutics Inc. $750.00 08/06/2025 Non-covered Recipient Entity
Banner MD Anderson Cancer Center
A Phase 1b/2 Study of Selinexor (KPT-330) in Combination with Backbone Treatments for Resistant/Refractory Multiple Myeloma No dispute reported 06/30/2026 1246662718
Principal investigator 1 Karyopharm Therapeutics Inc. $3,445.00 08/06/2025 Non-covered Recipient Entity
Banner MD Anderson Cancer Center
A Phase 1b/2 Study of Selinexor (KPT-330) in Combination with Backbone Treatments for Resistant/Refractory Multiple Myeloma No dispute reported 06/30/2026 1246662726
Recipient PFIZER INC. $330.00 08/05/2025 Covered Recipient Physician ELRANATAMAB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228803142
Principal investigator 1 Janssen Research & Development, LLC $12,040.00 07/28/2025 Covered Recipient Teaching Hospital
Banner Casa Grande Medical Center
A Phase 1 Randomized, Open-Label Pharmacokinetic Comparability Study Comparing Pre- and Post-change Teclistamab in Participants with Relapsed/Refractory Multiple Myeloma No dispute reported 06/30/2026 1175368578
Principal investigator 1 Janssen Research & Development, LLC $15,748.00 07/24/2025 Covered Recipient Teaching Hospital
Banner Casa Grande Medical Center
A Phase 1 Randomized, Open-Label Pharmacokinetic Comparability Study Comparing Pre- and Post-change Teclistamab in Participants with Relapsed/Refractory Multiple Myeloma No dispute reported 06/30/2026 1175368794
Principal investigator 1 Janssen Research & Development, LLC $11,182.00 07/21/2025 Covered Recipient Teaching Hospital
Banner Casa Grande Medical Center
A Phase 1 Randomized, Open-Label Pharmacokinetic Comparability Study Comparing Pre- and Post-change Teclistamab in Participants with Relapsed/Refractory Multiple Myeloma No dispute reported 06/30/2026 1175368626
Principal investigator 1 BeOne Medicines Ltd. $161.00 07/18/2025 Covered Recipient Teaching Hospital
Banner Casa Grande Medical Center
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190331843
Principal investigator 1 BeOne Medicines Ltd. $161.00 07/18/2025 Covered Recipient Teaching Hospital
Banner Casa Grande Medical Center
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190343255
Principal investigator 1 Karyopharm Therapeutics Inc. $400.00 07/03/2025 Non-covered Recipient Entity
Banner MD Anderson Cancer Center
A Phase 1b/2 Study of Selinexor (KPT-330) in Combination with Backbone Treatments for Resistant/Refractory Multiple Myeloma No dispute reported 06/30/2026 1246662702
Principal investigator 1 Karyopharm Therapeutics Inc. $400.00 07/03/2025 Non-covered Recipient Entity
Banner MD Anderson Cancer Center
A Phase 1b/2 Study of Selinexor (KPT-330) in Combination with Backbone Treatments for Resistant/Refractory Multiple Myeloma No dispute reported 06/30/2026 1246662710
Principal investigator 1 Janssen Research & Development, LLC $39,998.00 06/30/2025 Covered Recipient Teaching Hospital
Banner Casa Grande Medical Center
A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who have Received 1 to 3 Prior Lines of Ther No dispute reported 06/30/2026 1175368866
Principal investigator 2 BeOne Medicines Ltd. $52,400.00 06/25/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190330237
Principal investigator 2 BeOne Medicines Ltd. $293,440.00 06/25/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190330239
Principal investigator 1 Janssen Research & Development, LLC $7,179.00 06/23/2025 Covered Recipient Teaching Hospital
Banner Casa Grande Medical Center
A Phase 1 Randomized, Open-Label Pharmacokinetic Comparability Study Comparing Pre- and Post-change Teclistamab in Participants with Relapsed/Refractory Multiple Myeloma No dispute reported 06/30/2026 1175368818
Principal investigator 1 BeOne Medicines Ltd. $161.00 06/20/2025 Covered Recipient Teaching Hospital
Banner Casa Grande Medical Center
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190331281
Principal investigator 1 BeOne Medicines Ltd. $52,400.00 06/09/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190330269
Principal investigator 1 BeOne Medicines Ltd. $950.00 06/02/2025 Covered Recipient Teaching Hospital
Banner Casa Grande Medical Center
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190326258
Principal investigator 1 BeOne Medicines Ltd. $873.00 06/02/2025 Covered Recipient Teaching Hospital
Banner Casa Grande Medical Center
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190326274
Principal investigator 1 BeOne Medicines Ltd. $49.00 06/02/2025 Covered Recipient Teaching Hospital
Banner Casa Grande Medical Center
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190326278
Principal investigator 1 BeOne Medicines Ltd. $70.00 06/02/2025 Covered Recipient Teaching Hospital
Banner Casa Grande Medical Center
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190331259
Principal investigator 1 BeOne Medicines Ltd. $210.00 06/02/2025 Covered Recipient Teaching Hospital
Banner Casa Grande Medical Center
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190331289
Principal investigator 1 BeOne Medicines Ltd. $1,000.00 06/02/2025 Covered Recipient Teaching Hospital
Banner Casa Grande Medical Center
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190338773
Principal investigator 1 BeOne Medicines Ltd. $4.92 06/02/2025 Covered Recipient Teaching Hospital
Banner Casa Grande Medical Center
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190338789
Principal investigator 1 Janssen Research & Development, LLC $70,934.42 06/02/2025 Covered Recipient Teaching Hospital
Banner Casa Grande Medical Center
A Phase 1 Randomized, Open-Label Pharmacokinetic Comparability Study Comparing Pre- and Post-change Teclistamab in Participants with Relapsed/Refractory Multiple Myeloma No dispute reported 06/30/2026 1175368531
Principal investigator 1 Janssen Research & Development, LLC $16,391.00 06/02/2025 Covered Recipient Teaching Hospital
Banner Casa Grande Medical Center
A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who have Received 1 to 3 Prior Lines of Ther No dispute reported 06/30/2026 1175368674
Principal investigator 1 Janssen Research & Development, LLC $26,115.00 05/26/2025 Covered Recipient Teaching Hospital
Banner Casa Grande Medical Center
A Phase 1 Randomized, Open-Label Pharmacokinetic Comparability Study Comparing Pre- and Post-change Teclistamab in Participants with Relapsed/Refractory Multiple Myeloma No dispute reported 06/30/2026 1175368616
Principal investigator 1 BeiGene, Ltd. $809.20 05/21/2025 Covered Recipient Teaching Hospital
Banner Casa Grande Medical Center
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190320736
Principal investigator 1 BeiGene, Ltd. $9.82 05/21/2025 Covered Recipient Teaching Hospital
Banner Casa Grande Medical Center
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190320752
Principal investigator 1 BeiGene, Ltd. $2,268.00 05/21/2025 Covered Recipient Teaching Hospital
Banner Casa Grande Medical Center
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190320772
Principal investigator 1 BeiGene, Ltd. $2,310.00 05/21/2025 Covered Recipient Teaching Hospital
Banner Casa Grande Medical Center
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190320856
Principal investigator 1 BeiGene, Ltd. $2,450.00 05/21/2025 Covered Recipient Teaching Hospital
Banner Casa Grande Medical Center
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190322966
Principal investigator 1 Janssen Research & Development, LLC $1,500.00 05/12/2025 Covered Recipient Teaching Hospital
Banner Casa Grande Medical Center
A Phase 1 Randomized, Open-Label Pharmacokinetic Comparability Study Comparing Pre- and Post-change Teclistamab in Participants with Relapsed/Refractory Multiple Myeloma No dispute reported 06/30/2026 1175368777
Principal investigator 1 BeiGene, Ltd. $478.80 04/25/2025 Covered Recipient Teaching Hospital
Banner Casa Grande Medical Center
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190320808
Principal investigator 1 Janssen Research & Development, LLC $28,130.64 04/21/2025 Covered Recipient Teaching Hospital
Banner Casa Grande Medical Center
A Phase 1 Randomized, Open-Label Pharmacokinetic Comparability Study Comparing Pre- and Post-change Teclistamab in Participants with Relapsed/Refractory Multiple Myeloma No dispute reported 06/30/2026 1175368517
Principal investigator 1 Janssen Research & Development, LLC $24,855.00 04/21/2025 Covered Recipient Teaching Hospital
Banner Casa Grande Medical Center
A Phase 1 Randomized, Open-Label Pharmacokinetic Comparability Study Comparing Pre- and Post-change Teclistamab in Participants with Relapsed/Refractory Multiple Myeloma No dispute reported 06/30/2026 1175368760
Principal investigator 1 Janssen Research & Development, LLC $7,311.00 04/21/2025 Covered Recipient Teaching Hospital
Banner Casa Grande Medical Center
A Phase 1 Randomized, Open-Label Pharmacokinetic Comparability Study Comparing Pre- and Post-change Teclistamab in Participants with Relapsed/Refractory Multiple Myeloma No dispute reported 06/30/2026 1175368850
Principal investigator 1 Janssen Research & Development, LLC $19,818.00 03/24/2025 Covered Recipient Teaching Hospital
Banner Casa Grande Medical Center
A Phase 1 Randomized, Open-Label Pharmacokinetic Comparability Study Comparing Pre- and Post-change Teclistamab in Participants with Relapsed/Refractory Multiple Myeloma No dispute reported 06/30/2026 1175368554
Principal investigator 1 BeiGene, Ltd. $52,400.00 03/17/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190323680
Principal investigator 1 Janssen Research & Development, LLC $60,886.03 03/17/2025 Covered Recipient Teaching Hospital
Banner Casa Grande Medical Center
A Phase 1 Randomized, Open-Label Pharmacokinetic Comparability Study Comparing Pre- and Post-change Teclistamab in Participants with Relapsed/Refractory Multiple Myeloma No dispute reported 06/30/2026 1175368562
Principal investigator 1 Janssen Research & Development, LLC $114,619.00 03/17/2025 Covered Recipient Teaching Hospital
Banner Casa Grande Medical Center
A Phase 1 Randomized, Open-Label Pharmacokinetic Comparability Study Comparing Pre- and Post-change Teclistamab in Participants with Relapsed/Refractory Multiple Myeloma No dispute reported 06/30/2026 1175368647
Principal investigator 1 Janssen Research & Development, LLC $15,849.00 02/24/2025 Covered Recipient Teaching Hospital
Banner Casa Grande Medical Center
A Phase 1 Randomized, Open-Label Pharmacokinetic Comparability Study Comparing Pre- and Post-change Teclistamab in Participants with Relapsed/Refractory Multiple Myeloma No dispute reported 06/30/2026 1175368810
Principal investigator 1 Karyopharm Therapeutics Inc. $1,050.00 02/04/2025 Non-covered Recipient Entity
Banner MD Anderson Cancer Center
A Phase 1b/2 Study of Selinexor (KPT-330) in Combination with Backbone Treatments for Resistant/Refractory Multiple Myeloma No dispute reported 06/30/2026 1246662704
Principal investigator 1 Karyopharm Therapeutics Inc. $400.00 02/04/2025 Non-covered Recipient Entity
Banner MD Anderson Cancer Center
A Phase 1b/2 Study of Selinexor (KPT-330) in Combination with Backbone Treatments for Resistant/Refractory Multiple Myeloma No dispute reported 06/30/2026 1246662720
Principal investigator 1 Karyopharm Therapeutics Inc. $1,852.00 02/04/2025 Non-covered Recipient Entity
Banner MD Anderson Cancer Center
A Phase 1b/2 Study of Selinexor (KPT-330) in Combination with Backbone Treatments for Resistant/Refractory Multiple Myeloma No dispute reported 06/30/2026 1246662722
Principal investigator 1 Karyopharm Therapeutics Inc. $800.00 02/04/2025 Non-covered Recipient Entity
Banner MD Anderson Cancer Center
A Phase 1b/2 Study of Selinexor (KPT-330) in Combination with Backbone Treatments for Resistant/Refractory Multiple Myeloma No dispute reported 06/30/2026 1246662724
Principal investigator 1 Janssen Research & Development, LLC $38,917.00 01/20/2025 Covered Recipient Teaching Hospital
Banner Casa Grande Medical Center
A Phase 1 Randomized, Open-Label Pharmacokinetic Comparability Study Comparing Pre- and Post-change Teclistamab in Participants with Relapsed/Refractory Multiple Myeloma No dispute reported 06/30/2026 1175368545
Principal investigator 1 Janssen Research & Development, LLC $5,522.00 01/17/2025 Covered Recipient Teaching Hospital
Banner Casa Grande Medical Center
A Phase 1 Randomized, Open-Label Pharmacokinetic Comparability Study Comparing Pre- and Post-change Teclistamab in Participants with Relapsed/Refractory Multiple Myeloma No dispute reported 06/30/2026 1175368537
Principal investigator 1 BeiGene, Ltd. $1,304.80 01/15/2025 Covered Recipient Teaching Hospital
Banner Casa Grande Medical Center
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190324350
Principal investigator 1 BeiGene, Ltd. $2,400.00 01/06/2025 Covered Recipient Teaching Hospital
Banner Casa Grande Medical Center
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190320024
Principal investigator 1 BeiGene, Ltd. $20.47 01/06/2025 Covered Recipient Teaching Hospital
Banner Casa Grande Medical Center
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190324244